Zydus Wellness Limited
Momentum (83/100) does the heavy lifting; valuation (7/100) is the drag.
ExpensiveOvervaluedZydus Wellness Limited earns a Sell from StocksWizard, with a blended score of 41/100. At ₹577.55 it trades above our blended DCF and relative-multiples fair value of ₹288.77, about 50% downside to that estimate — we read it as overvalued by 50%. On 84.8x trailing earnings it sits pricier than the Consumer Defensive median of about 26.1x. The price is about 4% below its 52-week high of ₹602.5 and 55% above the low of ₹372.76. Financial health scores 49/100, in the grey band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹564.29 implies about 2% downside across 7 analysts. It clears 4 of 13 investability checks, with durability 36, valuation 13 and momentum 83 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹231.02.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-4.14% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell41Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 3.4%
- Fail: Low debt (D/E < 0.5): 0.55x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 63%
- Fail: Earnings growing: -6%
- Fail: Net margin ≥ 10%: 5.0%
- Pass: Current ratio > 1.5: 1.88
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Fail: Altman Z in safe zone: Z 2.97
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter69.8%
- Institutions20.6%
- Public & other9.5%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Opportunities
- Revenue growing (63% YoY).
Bear case
Weaknesses
- Low return on equity (3.4%).
Threats
- Earnings contracting year on year.
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About Zydus Wellness Limited
Zydus Wellness Limited engages in the development, production, marketing, and distribution of health and wellness products in India, the Middle East, Asia, Africa, the Oceania, and internationally. It provides sugar substitute products under the Sugar Free Gold, Sugar Free Natura, and Sugar Free Green brands; milk-based health food drink under the Complan brand; glucose-based beverage under the Glucon-D brand; and I'm lite a blended sugar coated with stevia. The company also
Zydus Wellness Limited — frequently asked questions
Is Zydus Wellness Limited a buy, hold or sell?
StocksWizard currently rates Zydus Wellness Limited (ZYDUSWELL) a Sell, based on a blended score of 41/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Zydus Wellness Limited's fair value?
Our blended DCF and relative-valuation model estimates Zydus Wellness Limited's fair value at about ₹288.77, versus a current price of ₹577.55 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is Zydus Wellness Limited financially healthy?
Zydus Wellness Limited scores 49/100 on our financial-health model, placing it in the grey band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Zydus Wellness Limited's share price performed?
Zydus Wellness Limited is up 15% over three months, and last traded at ₹577.55. Past performance doesn't predict future returns.
More in Consumer Defensive
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.